J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback

The roundup reports a successful Phase 3 study for BMS alongside mixed late-stage pulmonary fibrosis findings. It also says responses to Revolution Medicines’ recently approved pancreatic cancer medicine differed by mutation, with better results in some patient groups.